This inventor holds 1 USPTO granted patent. Top assignee: Novartis Vaccines & Diagnostics, Gmbh. Active years: 2006.
Company Filing History:
Years Active: 2006
Title: The Innovative Contributions of Sharon A Chen
Introduction
Sharon A Chen is a notable inventor based in Mountain View, CA (US). She has made significant contributions to the field of medical treatments, particularly in addressing articular cartilage disorders. Her innovative approach has the potential to improve the quality of life for many individuals suffering from these conditions.
Latest Patents
Sharon A Chen holds a patent for "Compositions and methods for treating articular cartilage disorders." This patent describes a method for treating mammalian articular cartilage disorders, specifically osteoarthritis and trauma-related cartilage injuries. The method involves increasing the amount of insulin-like growth factor I (IGF-I) at the affected site to a therapeutically effective level. This approach aims to maintain and regenerate cartilage, which is crucial for the long-term treatment of osteoarthritis and related injuries. The patent outlines that single doses of at least 0.01 mg of pharmaceutically effective IGF-I should be administered intermittently, with a recommended frequency of about once per week or less.
Career Highlights
Sharon A Chen is currently employed at Novartis Vaccines & Diagnostics GmbH, where she continues to work on innovative solutions in the medical field. Her expertise and dedication to research have positioned her as a valuable asset in her organization.
Collaborations
Sharon collaborates with esteemed colleagues, including Marilyn C Pike and Grushenka H I Wolfgang. These partnerships enhance her research efforts and contribute to the advancement of medical treatments.
Conclusion
Sharon A Chen's work exemplifies the impact of innovation in medicine, particularly in the treatment of cartilage disorders. Her patent and ongoing research efforts reflect her commitment to improving patient outcomes and advancing medical science.